Bristol-Myers Squibb Company
METHODS OF TREATING TUMORS
Last updated:
Abstract:
The disclosure provides pharmaceutical compositions comprising an anti-PD-1 antibody or an anti-PD-L1 antibody. In some aspects, the pharmaceutical compositions are formulated for subcutaneous delivery. In some aspects, the pharmaceutical compositions further comprise an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering a pharmaceutical composition comprising an anti-PD-1 antibody or an anti-PD-L1 antibody.
Status:
Application
Type:
Utility
Filling date:
27 Dec 2021
Issue date:
28 Jul 2022